Cargando…

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells

Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Wu, Xiaowu Jenifer, Hassouna, Amira, Wang, Kelvin Sheng, Li, Yan, Feng, Tao, Zhao, Yu, Jin, Minfeng, Zhang, Baohong, Ying, Tianlei, Li, Jinyao, Cheng, Lufeng, Liu, Johnson, Huang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265583/
https://www.ncbi.nlm.nih.gov/pubmed/37324167
http://dx.doi.org/10.3892/br.2023.1629
_version_ 1785058563602776064
author Lu, Jun
Wu, Xiaowu Jenifer
Hassouna, Amira
Wang, Kelvin Sheng
Li, Yan
Feng, Tao
Zhao, Yu
Jin, Minfeng
Zhang, Baohong
Ying, Tianlei
Li, Jinyao
Cheng, Lufeng
Liu, Johnson
Huang, Yue
author_facet Lu, Jun
Wu, Xiaowu Jenifer
Hassouna, Amira
Wang, Kelvin Sheng
Li, Yan
Feng, Tao
Zhao, Yu
Jin, Minfeng
Zhang, Baohong
Ying, Tianlei
Li, Jinyao
Cheng, Lufeng
Liu, Johnson
Huang, Yue
author_sort Lu, Jun
collection PubMed
description Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC-1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti-proliferation effect in MIA PaCa-2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non-cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment.
format Online
Article
Text
id pubmed-10265583
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-102655832023-06-15 Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells Lu, Jun Wu, Xiaowu Jenifer Hassouna, Amira Wang, Kelvin Sheng Li, Yan Feng, Tao Zhao, Yu Jin, Minfeng Zhang, Baohong Ying, Tianlei Li, Jinyao Cheng, Lufeng Liu, Johnson Huang, Yue Biomed Rep Articles Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC-1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti-proliferation effect in MIA PaCa-2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non-cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment. D.A. Spandidos 2023-06-01 /pmc/articles/PMC10265583/ /pubmed/37324167 http://dx.doi.org/10.3892/br.2023.1629 Text en Copyright: © Lu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Lu, Jun
Wu, Xiaowu Jenifer
Hassouna, Amira
Wang, Kelvin Sheng
Li, Yan
Feng, Tao
Zhao, Yu
Jin, Minfeng
Zhang, Baohong
Ying, Tianlei
Li, Jinyao
Cheng, Lufeng
Liu, Johnson
Huang, Yue
Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
title Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
title_full Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
title_fullStr Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
title_full_unstemmed Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
title_short Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
title_sort gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265583/
https://www.ncbi.nlm.nih.gov/pubmed/37324167
http://dx.doi.org/10.3892/br.2023.1629
work_keys_str_mv AT lujun gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT wuxiaowujenifer gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT hassounaamira gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT wangkelvinsheng gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT liyan gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT fengtao gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT zhaoyu gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT jinminfeng gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT zhangbaohong gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT yingtianlei gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT lijinyao gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT chenglufeng gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT liujohnson gemcitabinefucoxanthincombinationinhumanpancreaticcancercells
AT huangyue gemcitabinefucoxanthincombinationinhumanpancreaticcancercells